Antibody-drug conjugates (ADCs) are a novel class of targeted cancer therapy that combines an antibody specific to cancer cells with a cytotoxic drug. This approach allows for direct delivery of the toxic agent to cancer cells, minimizing damage to healthy tissue. An example is trastuzumab emtansine, used in HER2-positive breast cancer.
